الفهرس 
Hereditary nonpolyposis colorectal cancer (HNPCC)Only 14 pages are availabe for public view
 |  | from | 157 |  |  |
| | | from | 157 | | |
Abstract
Colorectal carcinoma (CRC) represents the fourth most common type of cancer world-wide and the second leading cause of cancer-related death in the Western world. (1) In Egypt, according to the Middle East Cancer Consortium, based on data collected between 1999 and 2001, colorectal cancer constituted 4.4 percent of cancer cases in Egypt, which is affecting six in every 100,000 Egyptians, compared to 32 in every 100,000Americans.(2) The combination of Oxaliplatin (OXL) whether with 5, flurouracil, leucovorin (FOLFOX regimen) or capecitabine (XELOX regimen) has shown substantial benefit both in adjuvant setting as well as in treatment of advanced CRC in terms of prolonged disease-free and overall survival.(3 , 4) However, oxaliplatin-induced peripheral neuropathy (OXLIPN) is dose-limiting and has been a major concern that could have a negative impact on treatment outcome and the patient’s quality of life. (5)